Diclofenac composition

A technology of diclofenac and diclofenac potassium, applied in the directions of drug combination, drug delivery, antidote, etc.

Inactive Publication Date: 2015-10-07
THEMIS MEDICARE LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0020] It is evident from the details mentioned above that the injection formulation of diclofenac and its production is still a challenging task

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diclofenac composition
  • Diclofenac composition
  • Diclofenac composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] In a suitable vessel, prepare a solution containing diclofenac sodium at a concentration of 7.5% by adding 50% carbitol and 2% benzyl alcohol to previously boiled and cooled water and stirring well until the API is fully dissolved. If necessary, the pH of the solution is adjusted to the desired range by a suitable buffer such as Tris buffer, phosphate buffer such as sodium phosphate and optionally other alkalizing agents such as sodium hydroxide may be used. The solution was further diluted to final volume with sufficient water. Final volumes of solution are decanted into ampoules and multi-dose vials aseptically and under a continuous nitrogen blanket.

[0083] The prepared solution consisted of about 52% non-aqueous solution and 48% aqueous solution. A solution containing 20% ​​diclofenac sodium, corresponding to a 200 mg / mL solution, was similarly prepared.

Embodiment 2

[0085] Heat water in a suitable vessel at 80 to 85°C and cool to room temperature. A solution was prepared by dissolving 7.5% diclofenac sodium together with 30% carbitol and 2% benzyl alcohol in 50% water with continuous vigorous stirring until a clear solution was obtained. The pH is adjusted within the desired range of 7.5 to 9 by a suitable buffer such as Tris buffer, phosphate buffer such as sodium phosphate or alternatively by other alkalizing agents. The solution was further diluted to volume by qs. water. The final volume of the solution is sterilized by sterile filtration using a 0.22 μm filter and poured into ampoules and multi-dose vials. This process was all done under a constant nitrogen purge.

[0086] The prepared solution contained approximately 32% non-aqueous solution and 68% aqueous solution. The resulting liquid containing 75 mg of diclofenac sodium in 1 ml can be administered by injection by I.M and I.V routes.

Embodiment 3

[0088] In a suitable vessel, 30% of the carbitol is added to 50% of the water which is initially heated at 80 to 85°C and allowed to cool at room temperature. The solution was then stirred well with the addition of diclofenac sodium at a concentration of 7.5%. After mixing the ingredients in solution, it was further diluted with sufficient water to the desired final volume such that the final liquid consisted of 75 mg of diclofenac sodium in 1 ml. The resulting liquid was sterile filtered by using a 0.2 μm membrane. The pH of the solution is maintained in the desired range of 7.5 to 9 by adding a suitable alkalizing agent or buffer such as Tris buffer or phosphate buffer such as sodium phosphate, potassium phosphate. The entire process is carried out under a nitrogen blanket to remove oxygen.

[0089] The prepared solution contained about 30% non-aqueous solution and 70% aqueous solution. The resulting solution is ready to be filled into ampoules and multi-dose vials. It w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates a composition comprising Diclofenac and salts thereof wherein Diclofenac or its slats are present in an amount of 25 - 200 mg. The composition is suitable for the parenteral administration through intramuscular, intravenous route; also for oral, dermal, subcutaneous, cutaneous, nasal, ocular drops, as rectal suppository, vaginal pessaries, intra-articular, and otic delivery. The invention also provides compositions comprising a combination of Diclofenac and other drugs. The invention further provides a method for preparing said composition.

Description

technical field [0001] The present invention relates to compositions comprising diclofenac and salts thereof. Specifically, the present invention provides a composition comprising 25-200 mg of diclofenac or a salt thereof, suitable for parenteral administration via intramuscular or intravenous routes; also suitable for oral, transdermal, subcutaneous, skin, nasal, eye drops , as rectal suppository, vaginal suppository, intra-articular and intraaural delivery. The present invention also provides compositions comprising the combination of diclofenac and other drugs. The invention further provides methods for preparing said compositions. Background technique [0002] Diclofenac has structural characteristics of arylalkanoic acid agents and exhibits anti-inflammatory, analgesic and antipyretic activities. Diclofenac is unique among non-steroidal anti-inflammatory drugs (NSAIDs) because of its ability to inhibit arachidonic acid epoxidation leading to decreased production of p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K47/10A61K31/196A61P29/00
CPCA61K47/10A61K9/0019A61K31/167A61K31/196A61K31/215A61K45/06A61P19/02A61P27/06A61P29/00A61P39/00A61K2300/00
Inventor 迪尼什·尚蒂拉尔·帕特尔萨钦·迪尼什·帕特尔沙希坎特·普拉布达斯·库拉尼马达夫拉尔·戈文德拉尔·帕特尔
Owner THEMIS MEDICARE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products